journal article·2018-05-30Open access

pH-Controlled Liposomes for Enhanced Cell Penetration in Tumor Environment

Michela Barattin, Andrea Mattarei, Anna Balasso, Cristina Paradisi, Laura Cantù, Elena Del Favero, Tapani Viitala, Francesca Mastrotto, Paolo Caliceti, Stefano Salmaso

ACS Applied Materials & Interfaces· Volume 10· Issue 21

Abstract

An innovative pH-switchable colloidal system that can be exploited for site-selective anticancer drug delivery has been generated by liposome decoration with a new novel synthetic non-peptidic oligo-arginine cell-penetration enhancer (CPE) and a quenching PEGylated counterpart that detaches from the vesicle surface under the acidic conditions of tumors. The CPE module (Arg4-DAG) is formed by four arginine units conjugated to a first-generation (G1) 2,2-bis(hydroxymethyl)propionic acid (bis-MPA)/2,2-bis(aminomethyl)propionic acid (bis-AMPA) polyester dendron terminating with 1,2-distearoyl-3-azidopropane for liposome bilayer insertion. The zeta potential of the Arg4-DAG-decorated liposomes increased up to +32 mV as the Arg4-DAG/lipids molar ratio increased. The Arg4-DAG liposome shielding at pH 7.4 was provided by methoxy-PEG5 kDa-polymethacryloyl sulfadimethoxine (mPEG5 kDa-SDM8) with 7.1 apparent pKa. Zeta potential, surface plasmon resonance and synchrotron small-angle X-ray scattering analyses showed that at pH 7.4 mPEG5 kDa-SDM8 associates with polycationic Arg4-DAG-decorated liposomes yielding liposomes with neutral zeta potential. At pH 6.5, which mimics the tumor environment, mPEG5 kDa-SDM8 detaches from the liposome surface yielding Arg4-DAG exposure. Flow cytometry and confocal microscopy showed a 30-fold higher HeLa cancer cell association of the Arg4-DAG-decorated liposomes compared to non-decorated liposomes. At pH 7.4, the mPEG5 kDa-SDM8-coated liposomes undergo low cell association while remarkable cell association occurred at pH 6.5, which allowed for the controlled intracellular delivery of model macromolecules and small molecules loaded in the liposome under tumor conditions.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, Padova 35131, Italy

Department of Chemical Sciences, University of Padova, Via F. Marzolo 1, Padova 35131, Italy

Department of Medical Biotechnologies and Traslational Medicine, University of Milano, LITA, Via F.lli Cervi, 93, Segrate 20090, Italy

Centre for Drug Research and Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5, Helsinki FI-00014, Finland

Funding

European Social Fund · Universit? degli Studi di Padova

References (70)

Show source-provided references
1. 10.1038/nrd198410.1038/nrd1984 ↗
2. 10.1016/j.jconrel.2014.12.03010.1016/j.jconrel.2014.12.030 ↗
3. 10.1016/j.colsurfb.2011.10.03910.1016/j.colsurfb.2011.10.039 ↗
4. Tannock I. F. · Cancer Res. · 1989 · 49 · 4373
5. Norton K.-A. · Am. J. Cancer Res. · 2015 · 5 · 1295
6. 10.1073/pnas.140238311110.1073/pnas.1402383111 ↗
7. 10.1016/S0168-3659(02)00206-710.1016/S0168-3659(02)00206-7 ↗
8. 10.1086/34452810.1086/344528 ↗
9. 10.1515/ejnm-2013-000510.1515/ejnm-2013-0005 ↗
10. 10.1016/j.peptides.2014.04.01510.1016/j.peptides.2014.04.015 ↗
11. 10.1016/j.molmed.2012.04.01210.1016/j.molmed.2012.04.012 ↗
12. 10.1155/2011/41472910.1155/2011/414729 ↗
13. 10.1016/j.jconrel.2013.05.00110.1016/j.jconrel.2013.05.001 ↗
14. 10.1007/s00018-013-1517-810.1007/s00018-013-1517-8 ↗
15. 10.1016/j.febslet.2009.11.04610.1016/j.febslet.2009.11.046 ↗
16. 10.1021/bi100642n10.1021/bi100642n ↗
17. 10.1016/j.bbamem.2010.03.00510.1016/j.bbamem.2010.03.005 ↗
18. 10.1016/j.bbamem.2007.03.02910.1016/j.bbamem.2007.03.029 ↗
19. 10.1021/bc900081e10.1021/bc900081e ↗
20. 10.1016/S0167-8140(84)80077-810.1016/S0167-8140(84)80077-8 ↗
21. 10.1021/ja207073610.1021/ja2070736 ↗
22. 10.1016/j.ejpb.2012.11.00210.1016/j.ejpb.2012.11.002 ↗
23. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
24. 10.1021/acs.langmuir.5b0411110.1021/acs.langmuir.5b04111 ↗
25. 10.1016/j.ejpb.2016.10.01010.1016/j.ejpb.2016.10.010 ↗
26. 10.1021/la404662210.1021/la4046622 ↗
27. 10.1016/j.ijmm.2007.01.00510.1016/j.ijmm.2007.01.005 ↗
28. 10.1021/bc060080h10.1021/bc060080h ↗
29. 10.1016/j.jconrel.2006.12.00810.1016/j.jconrel.2006.12.008 ↗
30. 10.1016/j.jconrel.2008.04.02410.1016/j.jconrel.2008.04.024 ↗
31. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
32. 10.1155/2013/37425210.1155/2013/374252 ↗
33. 10.1016/j.bbamem.2005.11.01610.1016/j.bbamem.2005.11.016 ↗
34. 10.1073/pnas.92.6.205610.1073/pnas.92.6.2056 ↗
35. 10.1016/j.biomaterials.2011.11.05410.1016/j.biomaterials.2011.11.054 ↗
36. 10.1073/pnas.97.24.1300310.1073/pnas.97.24.13003 ↗
37. 10.1039/b719868j10.1039/b719868j ↗
38. 10.1016/S0168-3659(04)00184-110.1016/S0168-3659(04)00184-1 ↗
39. 10.1016/S0168-3659(02)00021-410.1016/S0168-3659(02)00021-4 ↗
40. 10.1021/bm050357110.1021/bm0503571 ↗
41. 10.1124/jpet.103.06022810.1124/jpet.103.060228 ↗
42. 10.1016/S0005-2736(01)00357-110.1016/S0005-2736(01)00357-1 ↗
43. 10.1002/bip.2098910.1002/bip.20989 ↗
44. 10.1016/j.jconrel.2011.12.00210.1016/j.jconrel.2011.12.002 ↗
45. 10.2147/IJN.S5343210.2147/IJN.S53432 ↗
46. SAKAGUCHI S. · J. Biochem. · 1925 · 5 · 13
47. 10.1016/j.bpj.2010.08.02910.1016/j.bpj.2010.08.029 ↗
48. 10.1002/pro.264710.1002/pro.2647 ↗
49. 10.1021/nn100560p10.1021/nn100560p ↗
50. 10.4149/gpb_2009_02_12610.4149/gpb_2009_02_126 ↗
51. 10.1016/j.bbamem.2012.06.01910.1016/j.bbamem.2012.06.019 ↗
52. 10.1039/C3990000152610.1039/C39900001526 ↗
53. 10.1007/s13346-016-0320-010.1007/s13346-016-0320-0 ↗
54. Connors K. A. · 1987
55. Tinoco I. · 1995
56. 10.1016/j.bbamem.2009.11.00710.1016/j.bbamem.2009.11.007 ↗
57. 10.1016/j.colsurfb.2012.05.03210.1016/j.colsurfb.2012.05.032 ↗
58. 10.1016/0167-4889(93)90137-E10.1016/0167-4889(93)90137-E ↗
59. 10.3390/pharmaceutics504054210.3390/pharmaceutics5040542 ↗
60. 10.1073/pnas.160824711310.1073/pnas.1608247113 ↗
61. 10.1016/j.tiv.2016.08.00210.1016/j.tiv.2016.08.002 ↗
62. 10.2147/IJN.S3890310.2147/IJN.S38903 ↗
63. 10.1016/j.bbamem.2004.02.00710.1016/j.bbamem.2004.02.007 ↗
64. 10.1021/bi960201910.1021/bi9602019 ↗
65. 10.1016/j.colsurfb.2009.05.01410.1016/j.colsurfb.2009.05.014 ↗
66. Yang N. J. · 2015 · 2910.1007/978-1-4939-2272-7_3 ↗
67. 10.1016/j.jconrel.2016.07.02410.1016/j.jconrel.2016.07.024 ↗
68. 10.1021/jp910077h10.1021/jp910077h ↗
69. 10.1186/1472-6750-2-910.1186/1472-6750-2-9 ↗
70. 10.1021/nn800330a10.1021/nn800330a ↗